Skip to main content
. 2020 Dec 11;11(12):1049. doi: 10.1038/s41419-020-03244-9

Fig. 1. The expression of NCAPH in cervical cancer and its association with patients’ prognosis.

Fig. 1

A The mRNA level of NCAPH in cervical cancer (CC) (n = 22) and normal cervix (NC) (n = 10) analyzed by real-time PCR. Data are presented as mean ± SD (n = 3). B, C) Immunohistochemical staining of NCAPH in normal cervix (NC) (n = 82), high-grade squamous intraepithelial lesion (HSIL) (n = 34) and invasive cervical cancer (ICC) (n = 165). Scale bars, 100 μm. D ROC curves showed the clear separation between normal cervix and cervical cancer tissues, with an area of 0.8826 (p = 0.0006). E NCAPH expression in several solid tumors analyzed by GEPIA data base. Normal, normal tissues; ESCA, esophageal carcinoma; BRCA, breast invasive adenocarcinoma; HNSC, head and neck squamous cell carcinoma and BLCA, bladder urothelial carcinoma. F Compared with LNM-negative cervical cancer (n = 104), NCAPH displayed higher expression rate in LNM-positive tissues (n = 61) (p = 0.0041). Kaplan–Meier curves for survival of 100 patients with cervical carcinoma. Culminative disease-free survival (G) and overall survival (H).